Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11210148 | 1.00 | MAPT (0.52) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11211602 | 1.00 | MAPT (0.52) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4965137 | 0.78 | SMN1; SMN2 (0.49) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9435169 | 0.76 | SMN1; SMN2 (0.50) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11038064 | 0.75 | MAPT (0.57) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12327881 | 0.74 | SMN1; SMN2 (0.47) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11681121 | 0.74 | KMT2A (0.55) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| Adonitol SCHEMBL19182208 | 0.73 | ALDH1A1 (0.38) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9651830 | 0.73 | MAPT (0.50) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10681604 | 0.72 | MAPT (0.51) | MAPTMAPK1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0245774-B1 | PROCESS FOR THE MANUFACTURE OF RIBITYLXYLIDINE | BASF Aktiengesellschaft (DE) | 1990-12-05 | — | — | EP | claimed |
| US-4806686-A | REACTING RIBOSE AND 3,4-DIMETHYLANILINE OR NITRO-O-XYLENE/4-/ IN BORIC ACID COMPOUND AND HYDROGENATION CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | claimed |
| US-7427619-B2 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | BURZYNSKI STANISLAW R | 2008-09-23 | — | — | US | disclosed |
| CN-100358527-C | Preparation containing amino acids and riboflavin for reducing toxic and side effects of cytotoxic chemotherapy | BURZYNSKI STANISLAV R (US) | 2008-01-02 | — | — | CN | disclosed |
| EP-1450781-B1 | FORMULATION OF AMINO ACIDS AND RIBOFLAVIN USEFUL TO REDUCE TOXIC EFFECTS OF CYTOTOXIC CHEMOTHERAPY | BURZYNSKI STANISLAW R (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050182064-A1 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | BURZYNSKI STANISLAW R (US) | 2005-08-18 | — | — | US | disclosed |
| CN-1596109-A | Preparation containing amino acids and riboflavin for reducing toxic and side effects of cytotoxic chemotherapy | BURZYNSKI STANISLAV R (US) | 2005-03-16 | — | — | CN | disclosed |
| EP-1450781-A1 | FORMULATION OF AMINO ACIDS AND RIBOFLAVIN USEFUL TO REDUCE TOXIC EFFECTS OF CYTOTOXIC CHEMOTHERAPY | Burzynski, Stanislaw R. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045372-A1 | FORMULATION OF AMINO ACIDS AND RIBOFLAVIN USEFUL TO REDUCE TOXIC EFFECTS OF CYTOTOXIC CHEMOTHERAPY | BURZYNSKI STANISLAW R (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030105104-A1 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | BURZYNSKI STANISLAW R (US) | 2003-06-05 | — | — | US | disclosed |
| EP-0245774-B1 | PROCESS FOR THE MANUFACTURE OF RIBITYLXYLIDINE | BASF Aktiengesellschaft (DE) | 1990-12-05 | — | — | EP | disclosed |
| EP-0245774-B1 | PROCESS FOR THE MANUFACTURE OF RIBITYLXYLIDINE | BASF Aktiengesellschaft (DE) | 1990-12-05 | — | — | EP | disclosed |
| US-4806686-A | REACTING RIBOSE AND 3,4-DIMETHYLANILINE OR NITRO-O-XYLENE/4-/ IN BORIC ACID COMPOUND AND HYDROGENATION CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | disclosed |
| US-4806686-A | REACTING RIBOSE AND 3,4-DIMETHYLANILINE OR NITRO-O-XYLENE/4-/ IN BORIC ACID COMPOUND AND HYDROGENATION CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | disclosed |
| EP-0245774-A2 | Process for the manufacture of ribitylxylidine | BASF Aktiengesellschaft (DE) | 1987-11-19 | — | — | EP | disclosed |
| EP-0245774-A2 | Process for the manufacture of ribitylxylidine | BASF Aktiengesellschaft (DE) | 1987-11-19 | — | — | EP | disclosed |
| EP-0020959-B1 | PROCESS FOR THE PREPARATION OF RIBOFLAVIN | MERCK PATENT GmbH (DE) | 1983-06-29 | — | — | EP | disclosed |
| US-4355158-A | Process for the preparation of riboflavin | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-10-19 | — | — | US | disclosed |
| EP-0020959-A1 | Process for the preparation of riboflavin | MERCK PATENT GmbH (DE) | 1981-01-07 | — | — | EP | disclosed |